NCT01264692 - Essential Hypertension | Biotech Hunter

Enrollment

196

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

February 29, 2012

Conditions

Essential Hypertension

Interventions

DRUG

ACT-280778

10 mg once daily for 28 ± 2 days

DRUG

Placebo

Placebo oral capsules matching ACT-280778

DRUG

Amlodipine

10 mg once daily for 28 ± 2 days

Trial Locations (18)

11000

Clinical Investigative Site 3001, Belgrade

Clinical InvestigativeSite 3003, Belgrade

11040

Clinical Investigative Site 4001, Belgrade

11080

Clinical Investigative Site 3004, Belgrade

Clinical Investigative Site 3002, Zemun

13100

Clinical Investigative Site 1005, Safed

16100

Clinical Investigative Site 1006, Nazareth

Clinical Investigative Site 1007, Nazareth

18101

Clinical Investigative Site 4000, Afula

18205

Clinical Investigative Site 3000, Niška Banja

26000

Clinical Investigative Site 4002, Pančevo

52621

Clinical Investigative Site 1012, Tel Litwinsky

53583

Clinical Investigative Site 1004, Giv‘atayim

58100

Clinical Investigative Site 1009, Holon

66872

Clinical Investigative Site 1010, Tel Aviv

78278

Clinical Investigative Site 1003, Ashkelon

84101

Clinical Investigative Site 1008, Beersheba

91004

Clinical Investigative Site 1000, Jerusalem